10-Q: Surmodics Reports Q2 2025 Results Amidst FTC Litigation Over Proposed Acquisition

Surmodics' Q2 2025 results reveal a revenue decrease and operating loss, overshadowed by ongoing legal challenges from the FTC regarding its acquisition by BCE Parent, LLC.

Summary

• Surmodics, Inc. reported a decrease in revenue for the second quarter of fiscal year 2025, with total revenue dropping to $28.1 million from $31.96 million in the same period last year.
• The company experienced an operating loss of $4.01 million for the quarter, compared to an operating income of $0.66 million in the prior year.
• For the first six months of fiscal 2025, revenue decreased to $58.01 million from $62.51 million in the prior year period.
• The operating loss for the first six months was $6.49 million, compared to an operating income of $0.34 million in the same period last year.
• The decrease in revenue was primarily driven by lower Medical Device sales, particularly SurVeil DCB product sales, partially offset by growth in the Pounce thrombectomy device platform.
• The company is currently involved in litigation with the FTC, which is seeking to block the proposed acquisition of Surmodics by BCE Parent, LLC.
• Merger-related charges of $2.5 million and $4.8 million were incurred during the second quarter and first six months of fiscal 2025, respectively.
• The company's cash and cash equivalents and available-for-sale investments totaled $31.1 million as of March 31, 2025, a decrease of $9.0 million from September 30, 2024.
• The company believes its existing cash, cash equivalents, available-for-sale investments, cash flow from operations, and revolving credit facility will provide sufficient liquidity to meet its cash needs for fiscal 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the revenue decrease, operating loss, FTC litigation, and declining cash position. However, the company has access to a revolving credit facility and believes it has sufficient liquidity for fiscal 2025.

Positives

• The Pounce thrombectomy device platform continues to show growth.
• The company continues to experience growth in customer utilization of its Serene hydrophilic coating.
• The company believes its existing cash, cash equivalents, available-for-sale investments, cash flow from operations, and revolving credit facility will provide sufficient liquidity to meet its cash needs for fiscal 2025.
• The company has an interest rate swap in place, fixing the interest rate on $25.0 million of its term loan at 10.205% through its maturity.

Negatives

• The company experienced a decrease in revenue and an operating loss for the second quarter of fiscal 2025.
• Medical Device product sales decreased significantly, primarily due to lower SurVeil DCB sales.
• The company expects SurVeil DCB product revenue to decline by approximately $7.0 million in fiscal 2025 compared to fiscal 2024.
• Merger-related charges have negatively impacted SG&A expenses.
• The company's cash and investments have decreased significantly.
• The FTC has filed a complaint seeking to block the proposed acquisition of Surmodics by BCE Parent, LLC.

Risks

• The ongoing litigation with the FTC poses a significant risk to the completion of the proposed acquisition.
• A decline in SurVeil DCB sales is expected to negatively impact revenue in fiscal 2025.
• The company's reliance on a small number of significant customers could impact financial results.
• The company faces risks associated with new product development and regulatory approval processes.
• Changing conditions and uncertainty in global markets including the impact of tariffs, sanctions, quotas, import restrictions, and other trade actions may adversely affect our operations and financial results.

Future Outlook

The company anticipates SG&A and R&D expenses will continue to be significant, primarily related to medical device sales and product development. The company expects SurVeil DCB product revenue to decline by approximately $7.0 million in fiscal 2025 from their fiscal 2024 level. The company believes that its existing cash and cash equivalents and available-for-sale investments, which totaled $31.1 million as of March 31, 2025, together with cash flow from operations and its revolving credit facility, will provide liquidity sufficient to meet its cash needs and fund its operations and planned capital expenditures for fiscal 2025.

Industry Context

The medical device industry is highly competitive and subject to regulatory approvals. Surmodics' performance is affected by the success of its customers' products that utilize its coating technologies, as well as its own vascular intervention products. The FTC's challenge to the acquisition reflects increasing scrutiny of mergers and acquisitions in the healthcare sector.

Comparison to Industry Standards

• It is difficult to compare Surmodics directly to industry standards without more specific information on comparable companies and projects.
• However, medical device companies of similar size often have R&D expenses that are a significant percentage of revenue, reflecting the need for continuous innovation.
• Gross margins in the medical device industry can vary widely depending on the type of product, manufacturing costs, and pricing strategies.
• Companies like Medtronic and Abbott, which are major customers of Surmodics, serve as benchmarks for revenue and profitability in the broader medical device market.

Legal Proceedings

• The company is currently involved in litigation with the FTC, which is seeking to block the proposed acquisition of Surmodics by BCE Parent, LLC.

Stakeholder Impact

• Shareholders face uncertainty due to the FTC litigation and the potential failure of the acquisition.
• Employees may be affected by the ongoing litigation and potential changes in the company's ownership.
• Customers may be impacted by any disruptions to the company's operations or product development.
• Suppliers and creditors may be affected by the company's financial performance and the outcome of the acquisition.

Next Steps

• The company will continue to defend against the FTC's challenge to the proposed acquisition.
• The company will focus on growing revenue from its Pounce thrombectomy device platform and other products.
• The company will manage its expenses and cash flow to ensure sufficient liquidity.

Key Dates

Keywords

Surmodics, FTC, Merger, Revenue, Operating Loss, SurVeil DCB, Medical Device, In Vitro Diagnostics, Pounce Thrombectomy, Financial Results